Gupta Suneel's Form 4 filing
Protagonist Therapeutics, Inc (PTGX) · filed Nov 27, 2024
- Accession no.
- 0001104659-24-123807
- Filed
- Nov 27, 2024
- Trade date
- Nov 25-26, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions and 5 derivative transactions. Open-market sales total $5.64M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gupta SuneelCIK 0001763923 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 | Common Stock | MOption exerciseAcquired | +45,000 | $7.38 | +$332,100 | 229,611 | Direct | |
| Nov 25, 2024 | Common Stock | MOption exerciseAcquired | +45,000 | $8.02 | +$360,900 | 274,611 | Direct | |
| Nov 25, 2024 | Common Stock | MOption exerciseAcquired | +85,000 | $7.80 | +$663,000 | 359,611 | Direct | |
| Nov 25, 2024 | Common Stock | SSaleDisposed | −103,437 | $46.04F3 | −$4,762,239.48 | 256,174 | Direct | |
| Nov 26, 2024 | Common Stock | MOption exerciseAcquired | +30,000 | $12.17 | +$365,100 | 286,174 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −19,191 | $45.50F4 | −$873,190.5 | 266,983 | Direct | |
| Nov 26, 2024 | Common Stock | MOption exerciseAcquired | +450 | $12.17 | +$5,476.5 | 267,433 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 | Common Stock | MOption exerciseDisposed | −45,000 | $0.00 | $0 | 0 | Direct | |
| Nov 25, 2024 | Common Stock | MOption exerciseDisposed | −45,000 | $0.00 | $0 | 0 | Direct | |
| Nov 25, 2024 | Common Stock | MOption exerciseDisposed | −85,000 | $0.00 | $0 | 0 | Direct | |
| Nov 26, 2024 | Common Stock | MOption exerciseDisposed | −30,000 | $0.00 | $0 | 93,750 | Direct | |
| Nov 26, 2024 | Common Stock | MOption exerciseDisposed | −450 | $0.00 | $0 | 93,300 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.